CN210604115U - Whole blood filtering device - Google Patents
Whole blood filtering device Download PDFInfo
- Publication number
- CN210604115U CN210604115U CN201921551820.4U CN201921551820U CN210604115U CN 210604115 U CN210604115 U CN 210604115U CN 201921551820 U CN201921551820 U CN 201921551820U CN 210604115 U CN210604115 U CN 210604115U
- Authority
- CN
- China
- Prior art keywords
- pad
- whole blood
- plasma
- blood
- filtration device
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The utility model provides a whole blood filter equipment, including chromatography device, storage extrusion device, lower cover and upper cover, the draw-in groove has been seted up to the upper surface of lower cover, store extrusion device including being fixed in the urceolus and the slip of draw-in groove bottom are located the inboard inner tube of urceolus, the open-top of inner tube, bottom are equipped with the screen cloth, the chromatography device includes the bottom plate, the bottom plate has detection initial end and detection terminal, from detection initial end to detection terminal edge stack in proper order has placed blood filter pad one, blood filter pad two, barrier film and plasma absorption pad. The utility model discloses absorption a large amount of or micro-plasma that can be very fast, application scope is wide, and separation efficiency is high, has avoided the repetitive operation, has saved the plenty of time, has important using value to some diseases that need in time to detect.
Description
Technical Field
The utility model belongs to the technical field of biological sample separation, more specifically relates to whole blood filter equipment.
Background
In vitro diagnosis is mainly based on the diagnosis of body fluids (blood, urine, saliva), and the samples for blood examination are mainly classified into whole blood, serum and plasma. The whole blood after anticoagulation treatment is whole blood, and is used for measurement of blood cells, blood routine, blood sedimentation and the like. The yellowish liquid obtained after removing blood cells is plasma, and is often used for measurement of blood coagulation, immunity, and the like.
The traditional plasma separation methods mainly comprise two methods, one method is to make whole blood containing anticoagulant stand, and settle and separate the whole blood to obtain supernatant plasma under the gravity action of red blood cells, and the method needs a long time to separate the blood plasma. The other method is to perform centrifugal separation on a whole blood sample containing an anticoagulant, wherein supernatant obtained by the centrifugal separation is plasma, the method can be realized only by using a centrifugal machine, the centrifugal machine needs to be installed in a horizontal fixed field and cannot be used in a portable mode, and the centrifugal force can damage red blood cells to cause hemolysis.
In the chinese patent with application number CN201710196864.9, separate plasma through erythrocyte monoclonal antibody and EDTA anticoagulant and erythrocyte reaction, use glass fiber as plasma absorption material, glass fiber self needs to absorb plasma, the ability of absorbing plasma after saturation is limited, after some plasma of mounting hole gathering, take out plasma and put in the holding vessel, continue to wait to get again after the gathering, lead to complex operation, plasma separation time is long, and separation efficiency is low, be unfavorable for extracting, can not satisfy the demand that detects in time.
SUMMERY OF THE UTILITY MODEL
In view of this, the utility model aims at providing a whole blood filter equipment realizes the absorption and the storage of trace whole blood quickly separating plasma, reduces plasma separation time, improves separation efficiency, and high-efficient storage and extraction plasma.
In order to achieve the above purpose, the technical scheme of the utility model is realized like this:
whole blood filter equipment, including chromatography device, storage extrusion device, lower cover and upper cover, the draw-in groove has been seted up to the upper surface of lower cover, store extrusion device including being fixed in the urceolus of draw-in groove bottom locates with sliding the inboard inner tube of urceolus, the urceolus is the lower part and sets up jagged cylindric structure, the open-top of inner tube, the bottom is equipped with the screen cloth, chromatography device includes the bottom plate, the bottom plate has detection initial end and detection terminal, from detection initial end to detection terminal edge stack in proper order has placed blood filter pad one, blood filter pad two, barrier film and plasma absorption pad, the plasma absorption pad is located the superiors, the detection terminal of bottom plate passes the breach makes the plasma absorption pad is located the inboard of urceolus, on cover and seted up application hole and mounting hole, on the upper cover is located on the lower cover, it passes to store extrusion device the mounting hole, the sample adding hole is opposite to the first blood filtering pad.
Furthermore, the outer side wall of the inner barrel is symmetrically provided with two buckles with elasticity, and the inner side wall of the outer barrel is provided with a clamping groove matched with the buckles.
Further, the top of the inner cylinder is provided with a sealing cover which can be opened and closed.
Further, the screen mesh area of the screen mesh is 0.6mm2-1.5mm2。
Further, the plasma absorption pad is a cellulose sponge pad.
Further, the isolating membrane is a hydrophilic polyether sulfone resin membrane with an asymmetric structure, and the pore diameter of the hydrophilic polyether sulfone resin membrane is 0.03-10 mu m.
Furthermore, the second blood filtering pad is mixed fiber, and the second blood filtering pad is coated with erythrocyte monoclonal antibody.
Further, the first blood filter pad is made of glass fiber, and the first blood filter pad is coated with the erythrocyte monoclonal antibody.
Furthermore, the first blood filtering pad, the second blood filtering pad, the isolating membrane and the plasma absorption pad are respectively connected with the bottom plate in a sticking way.
Furthermore, the first blood filtering pad and the second blood filtering pad are connected, the second blood filtering pad and the isolating membrane are connected, and the isolating membrane and the plasma absorption pad are connected in a sticking mode.
Compared with the prior art, whole blood filter equipment have following advantage:
1. the utility model discloses set up and stored extrusion device, through the manual inner tube that pushes down, extrude and store the inner tube to the efficient follow plasma absorption pad of plasma under the external force extrusion, for the user provides convenience, separation efficiency is high, has avoided the repetitive operation, has saved a large amount of time, has important using value to some diseases that need in time to detect.
2. The utility model discloses use the cellulose foam-rubber cushion as plasma absorption pad, the inside developed pore structure of cellulose foam-rubber cushion has very strong hydrophilicity, adsorption affinity, cohesion and van der Waals' force, and the absorptive capacity is 1200% -2100%, can expand rapidly when absorbing plasma, stores a large amount of plasma, and the experiment proves, and the cellulose sponge can be very fast absorb a large amount of or micro-plasma, and application scope is wide.
Drawings
The accompanying drawings, which form a part hereof, are included to provide a further understanding of the invention, and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the invention without undue limitation. In the drawings:
fig. 1 is a schematic overall structure diagram of an embodiment of the present invention;
FIG. 2 is a schematic structural view of the embodiment of the present invention without the upper cover;
fig. 3 is a cross-sectional view of an embodiment of the present invention.
Description of reference numerals:
1. a lower cover; 2. an upper cover; 3. a card slot; 4. a base plate; 5. a plasma absorption pad; 6. an isolation film; 7. a second blood filtering pad; 8. a first blood filtering pad; 9. a sample application hole; 10. mounting holes; 11. an outer cylinder; 12. an inner barrel; 13. a notch; 14. screening a screen; 15. a sealing cover; 16. buckling; 17. a clamping groove.
Detailed Description
It should be noted that, in the present invention, the embodiments and features of the embodiments may be combined with each other without conflict.
In the description of the present invention, it is to be understood that the terms "center", "longitudinal", "lateral", "up", "down", "front", "back", "left", "right", "vertical", "horizontal", "top", "bottom", "inner", "outer", and the like, indicate orientations or positional relationships based on the orientations or positional relationships shown in the drawings, and are used merely for convenience of description and for simplicity of description, and do not indicate or imply that the device or element being referred to must have a particular orientation, be constructed and operated in a particular orientation, and therefore, should not be construed as limiting the present invention.
In the description of the present invention, it is to be noted that, unless otherwise explicitly specified or limited, the terms "mounted," "connected," and "connected" are to be construed broadly, and may be, for example, fixedly connected, detachably connected, or integrally connected; can be mechanically or electrically connected; they may be connected directly or indirectly through intervening media, or they may be interconnected between two elements. The specific meaning of the above terms in the present invention can be understood by those of ordinary skill in the art through specific situations.
The present invention will be described in detail below with reference to the accompanying drawings in conjunction with embodiments.
A whole blood filtration device, as shown in FIGS. 1 to 3, comprises a chromatography device, a storage-pressing device, a lower cap 1 and an upper cap 2. The upper surface of the lower cover 1 is provided with a rectangular clamping groove 173. The storage extrusion device comprises an outer cylinder 11 fixed at the bottom of the clamping groove 173 and an inner cylinder 12 arranged on the inner side of the outer cylinder 11 in a sliding manner. The outer cylinder 11 is a cylindrical structure with a notch 13 at the lower part, the top of the inner cylinder 12 is open, the bottom is provided with a screen 14, and the screen 14 has a screen mesh area of 0.6mm2-1.5mm2。
Chromatography device includes bottom plate 4 made by the PVC board, bottom plate 4 has detection initial end and detection terminal, certainly detection initial end to detection terminal edge stack in proper order has placed and has strained blood pad one 8, strain blood pad two 7, barrier film 6 and plasma absorption pad 5, plasma absorption pad 5 is located the superiors. The detection terminal of the bottom plate 4 penetrates through the notch 13 to enable the plasma absorption pad 5 to be located on the inner side of the outer barrel 11, the upper cover 2 is provided with a sample adding hole 9 and a mounting hole 10, the upper cover 2 is arranged on the lower cover 1, the storage extrusion device penetrates through the mounting hole 10, and the sample adding hole 9 is right aligned to the blood filtering pad 8.
The first blood filtering pad is made of glass fiber, and is coated with erythrocyte monoclonal antibody and EDTA anticoagulant (when EDTA anticoagulant is added into the whole blood sample, the first blood filtering pad is coated with erythrocyte monoclonal antibody).
The second blood filtering pad 7 is made of mixed fibers, the manufacturer is Oslon Shanghai division, and the model is Grade 1660, and the second blood filtering pad is coated with a red blood cell monoclonal antibody and an EDTA anticoagulant (when the whole blood sample is added with the EDTA anticoagulant, the second blood filtering pad is coated with the red blood cell monoclonal antibody).
When coating, the first or second filter pad is soaked in 0.01M pH7.4PBS buffer solution containing 0.1-10mg/mL erythrocyte monoclonal antibody and 0-2.2mg/mL EDTA anticoagulant, and then dried at 45 ℃ for 12 hours. Wherein the EDTA anticoagulant is EDTA-K2Or EDTA-Na2。
The isolation membrane 6 is a hydrophilic polyethersulfone resin membrane which is subjected to sulfonation hydrophilic treatment and has an asymmetric structure, and the aperture of the hydrophilic polyethersulfone resin membrane is 0.03-10 mu m.
The plasma absorption pad 5 is a cellulose sponge pad, the cellulose sponge pad is made of cellulose sponge, and the cellulose sponge is widely applied to ophthalmic surgery, minimally invasive surgery, surgical nursing and diagnostics and has certain safety. The cellulose sponge has strong water absorption, can increase the chromatographic force of whole blood filtration, reduce the separation time and improve the separation efficiency. The 1200-2100% of the blood plasma absorbing and storing capacity expands the range of the whole blood sample adding amount. And the cellulose sponge has stronger tensile strength, can bear tensile extrusion force, can release the sample of storing under the external force extrusion, according to this performance, through manual pressing the inner tube downwards, can extrude and store the inner tube to the efficient follow plasma absorption pad of sample, be convenient for extract and in time use, provide convenience for the user.
The top of the inner cylinder 12 is provided with a sealing cover 15 which can be opened and closed, and particularly, the sealing cover 15 can be connected with the inner cylinder 12 through a hinge.
Two elastic buckles 16 are symmetrically arranged on the outer side wall of the inner barrel 12, and a clamping groove 173 matched with the buckles 16 is arranged on the inner side wall of the outer barrel 11.
The first blood filtering pad 8, the second blood filtering pad 7, the isolating membrane 6 and the plasma absorption pad 5 are respectively connected with the bottom plate 4 in a sticking way.
The blood filtering pad I8 and the blood filtering pad II 7 are arranged between the blood filtering pad II 7 and the isolating membrane 6, and the isolating membrane 6 and the plasma absorption pad 5 are all connected in a sticking way.
During detection, a whole blood sample is dripped to the first blood filtering pad 8 through the sample adding hole 9, the whole blood sample sequentially passes through the first blood filtering pad 8, the second blood filtering pad 7 and the isolating membrane 6 to reach the plasma absorption pad 5, and the adsorption process is as follows:
a. whole blood sample at first with filter pad 8 peridium red blood cell monoclonal antibody and EDTA anticoagulant reaction, the EDTA anticoagulant has guaranteed that whole blood can not take place to agglutinate in the separation process, and the erythrocyte in the whole blood can take place specific immunological reaction with red blood cell monoclonal antibody, because glass fiber's irregular structure, most of red blood cell can adsorb at filter pad 8.
b. After most of red blood cells are adsorbed on the first blood filter pad 8, a small part of red blood cells react with the monoclonal antibody of the red blood cells and the EDTA anticoagulant which are coated on the second blood filter pad 7, most of red blood cells are adsorbed through the reaction of the first blood filter pad 8 and the second blood filter pad 7, and the red blood cells and plasma are promoted to be rapidly separated due to the fact that the mixed fiber with the flowability and the water absorption which are stronger than those of the first blood filter pad 8 is selected.
c. A small amount of free red blood cells are trapped in the second blood filter pad 7 by the physical action of the isolation membrane 6 through molecular sieves, only plasma can pass through and is finally adsorbed in the plasma absorption pad 5.
When the inner cylinder 12 is pressed down manually along the outer cylinder 11 after the plasma absorption pad 5 absorbs plasma, and the inner cylinder 12 is pressed to the bottom, the snap 16 is locked in the catch 173, and the plasma is extruded from the plasma absorption pad 5 through the gap of the screen 14 and stored in the inner cylinder 12. When testing is required, the sealing cover 15 is opened to draw the plasma from the inner cartridge 12.
Test example 1
1. Material
Erythrocyte monoclonal antibody, EDTA-K2The kit comprises a cellulose sponge pad, a hydrophilic PES membrane which is subjected to sulfonation hydrophilic treatment and has an asymmetric structure and a pore diameter of 3 mu m, mixed fibers, glass fibers and a whole blood sample.
Wherein the type of the cellulose sponge cushion is
Soaking the mixed fiber and glass fiber in a solution containing 0.1mg/mL erythrocyte monoclonal antibody and 2.2mg/mL EDTA-K20.01M pH7.4PBS buffer, and then dried at 45 ℃ for 12 hours after being sufficiently soaked.
2. Method of producing a composite material
Will be as shown in fig. 3, with glass fiber, mixed fiber, PES membrane, cellulose foam-rubber cushion edge overlap in proper order and paste and obtain semi-manufactured goods on the bottom plate, form in adorning the lower cover for 4mm bar with the semi-manufactured goods cutting the utility model discloses. Glass fiber, mixed fiber, PES film and untreated glass fiber are sequentially overlapped at the edges and pasted on a bottom plate to obtain a semi-finished product, the semi-finished product is cut into strips of 4mm and is installed in a lower cover to form a comparison group, and the specific structure of the comparison group is disclosed in Chinese patent with application number of CN 201710196864.9.
(1) 50, 100, 200, 300 μ L of whole blood samples were added to the wells of the present invention and the control group, respectively. Use the pipettor to follow after 3min stews the utility model discloses a suction separation plasma sample and survey in the mounting hole of urceolus, contrast group, the volume of getting plasma volume. The plasma separation rate was calculated according to the formula separation efficiency ═ separation volume/[ (1-hematocrit) × sample size ], and the experimental data are shown in tables 1 and 2, respectively.
(2) Add 300 mu L whole blood sample the utility model discloses and contrast group's application of sample hole, use the pipettor to follow after 1min, 2min, 3min stew respectively the utility model discloses an in the mounting hole suction separation plasma sample of urceolus, contrast group and survey, the volume of getting plasma volume. The plasma separation rate was calculated according to the formula separation efficiency ═ separation volume/[ (1-hematocrit) × sample size ], and the experimental data are shown in tables 3 and 4, respectively.
3. Results
As can be seen from Table 1, the separation efficiency of the present invention gradually increased with the increase of the sample volume, and when the sample volume was 300. mu.L, the separation efficiency reached 87.4%. Judge according to the experimental data, the utility model discloses an absorbent material cellulose sponge has strong adsorbability, not only is applicable to a small amount of sample separation, is applicable to a large amount of sample separations moreover, and the inner tube can be favorable to carrying out in time the detection in shorter time to the efficient extrusion of plasma in the absorbent material cellulose sponge.
As is clear from table 2, when the sample amount was 50 μ L, the separation ratio of the control group was 0%, because the adsorption property of the untreated glass fiber as the absorbent was weak, and the sample separation could not be performed in the control group. The separation rate of the control group is highest up to 58% when the sample size is 100. mu.L, and is reduced from 34% to 24.7% when the sample size is changed from 200 to 300. mu.L, because the excessive sample stays in the sample adding hole and the separation of the plasma is influenced.
TABLE 1 the utility model discloses the testing result of different sample volumes
TABLE 2 test results of different sample amounts in control group
As can be seen from the table 3, the utility model discloses the separation efficiency of different separation time remains stable, is about 79%, consequently explains the utility model discloses do not receive the influence of separation time length, can accomplish the separation in shorter separation time.
As can be seen from table 4, the separation efficiency of the control group increased from 22% to 63.3% with the increase of the separation time, indicating that the control group required a longer separation time to completely separate and the separation efficiency was low.
TABLE 3 detection results of different separation times
TABLE 4 test results for different separation times in control group
Test example 2
1. Material
PCT whole blood sample (No. S1-S10), Procalcitonin (PCT) detection kit by seiko bio-pharmaceuticals gmbh in tianjin (microfluidic immunofluorescence assay), and fluorescent immunoassay analyzer (FREND System) model F10 manufactured by korean nautai corporation.
2. Method of producing a composite material
10 parts of PCT whole blood sample are respectively divided into two parts, and the two parts are respectively separated by a centrifugal machine and the whole blood filtering device of the utility model. And (4) carrying out sample application detection on the separated blood plasma, and calculating the relative deviation of the detection result. The relative deviation was calculated according to the formula (detection value-control value) × 100%/control value, and the experimental data are shown in table 5.
3. Results
As can be seen from the table 5, the whole blood filtering device is basically consistent with the separation plasma detection result obtained by the centrifugal machine, and the separation device does not influence the plasma detection experiment result.
TABLE 5 PCT Whole blood sample test results
| Sample numbering | Centrifuge plasmametric value (ng/ml) | The utility model discloses the plasma measuring value (ng/ml) | Relative deviation of |
| S1 | 0.34 | 0.33 | -2.94％ |
| S2 | 0.48 | 0.5 | 4.17％ |
| S3 | 1.10 | 1.05 | -4.55％ |
| S4 | 3.62 | 3.54 | -2.21％ |
| S5 | 7.45 | 7.65 | 2.68％ |
| S6 | 9.34 | 9.64 | 3.21％ |
| S7 | 16.52 | 16.99 | 2.85％ |
| S8 | 19.24 | 20.01 | 4.00％ |
| S9 | 24.43 | 24.83 | 1.64％ |
| S10 | 29.87 | 28.98 | -2.98％ |
The above description is only a preferred embodiment of the present invention, and should not be taken as limiting the invention, and any modifications, equivalent replacements, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. Whole blood filter equipment, its characterized in that: including chromatography device, storage extrusion device, lower cover and upper cover, the draw-in groove has been seted up to the upper surface of lower cover, storage extrusion device is located including being fixed in the urceolus of draw-in groove bottom and sliding, the urceolus is the cylindric structure that the lower part was seted up jaggedly, the open-top of inner tube, the bottom is equipped with the screen cloth, chromatography device includes the bottom plate, the bottom plate has detection initial end and detection terminal, from detection initial end to detection terminal edge stack in proper order has placed filter pad one, filter pad two, barrier film and plasma absorption pad, plasma absorption pad is located the superiors, the detection terminal of bottom plate passes the breach makes plasma absorption pad is located the inboard of urceolus, on cover and seted up application hole and mounting hole, the upper cover is located on the lower cover, storage extrusion device passes the mounting hole, the sample adding hole is opposite to the first blood filtering pad.
2. The whole blood filtration device according to claim 1, wherein: the outer side wall of the inner barrel is symmetrically provided with two buckles with elasticity, and the inner side wall of the outer barrel is provided with a clamping groove matched with the buckles.
3. Whole blood filtration device according to claim 1 or 2, wherein: the top of the inner cylinder is provided with a sealing cover which can be opened and closed.
4. Whole blood filtration device according to claim 1 or 2, wherein: the mesh area of the screen is 0.6mm2-1.5mm2。
5. Whole blood filtration device according to claim 1 or 2, wherein: the plasma absorption pad is a cellulose sponge pad.
6. Whole blood filtration device according to claim 1 or 2, wherein: the isolating membrane is a hydrophilic polyether sulfone resin membrane with an asymmetric structure, and the pore diameter of the hydrophilic polyether sulfone resin membrane is 0.03-10 mu m.
7. Whole blood filtration device according to claim 1 or 2, wherein: the second blood filtering pad is mixed fiber, and the second blood filtering pad is coated with erythrocyte monoclonal antibody.
8. Whole blood filtration device according to claim 1 or 2, wherein: the first blood filtering pad is glass fiber, and the first blood filtering pad is coated with erythrocyte monoclonal antibody.
9. Whole blood filtration device according to claim 1 or 2, wherein: the first blood filtering pad, the second blood filtering pad, the isolating membrane and the plasma absorption pad are respectively connected with the base plate in a sticking way.
10. Whole blood filtration device according to claim 1 or 2, wherein: the blood filtering pad I and the blood filtering pad II are connected with each other, the blood filtering pad II and the isolating membrane are connected with each other in a sticking way, and the isolating membrane and the plasma absorption pad are connected with each other in a sticking way.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201921551820.4U CN210604115U (en) | 2019-09-18 | 2019-09-18 | Whole blood filtering device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201921551820.4U CN210604115U (en) | 2019-09-18 | 2019-09-18 | Whole blood filtering device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN210604115U true CN210604115U (en) | 2020-05-22 |
Family
ID=70687890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201921551820.4U Active CN210604115U (en) | 2019-09-18 | 2019-09-18 | Whole blood filtering device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN210604115U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114410441A (en) * | 2022-02-08 | 2022-04-29 | 浙江嘉孚生物科技有限公司 | Blood collection card and application thereof |
-
2019
- 2019-09-18 CN CN201921551820.4U patent/CN210604115U/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114410441A (en) * | 2022-02-08 | 2022-04-29 | 浙江嘉孚生物科技有限公司 | Blood collection card and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101181396B1 (en) | A vessel for sample organism | |
| EP1793906B1 (en) | Blood separator and method of separating a fluid fraction from whole blood | |
| CN104582571A (en) | Quick test device and method | |
| US20010044615A1 (en) | Plasma collecting device | |
| CN109439533B (en) | Separation device, separation control system and separation method | |
| EP1497663A1 (en) | Sample preparation of biological fluids for proteomic applications | |
| CN210604115U (en) | Whole blood filtering device | |
| US10716887B2 (en) | Filtration module | |
| JP2014157165A (en) | Liquid chromatography member | |
| US10758866B2 (en) | Isolation chip and manufacturing method of the same | |
| EP4063855A1 (en) | Multi-filter for separating blood components, and disease diagnosis kit using same | |
| CN110857904A (en) | Method for obtaining plasma from whole blood sample, hemofilter and microfluidic chip | |
| JPH0223831B2 (en) | ||
| WO1996024425A1 (en) | Peristaltic system and method for plasma separation | |
| CN204422302U (en) | Clinical examination smear machine | |
| JP3870468B2 (en) | Plasma or serum separation filter | |
| CN209968132U (en) | Filter membrane structure for whole blood filtration | |
| CN210136235U (en) | Whole blood sample detection device | |
| CN212586392U (en) | CRP/SAA combined detection kit | |
| CN213232220U (en) | A novel liquefaction post device for blood clot nucleic acid draws | |
| WO2019025914A1 (en) | Plasma separation device | |
| CN212731722U (en) | Membrane module and blood filtering device comprising same | |
| CN202875352U (en) | Vacuum blood sampling pipe capable of directly separating plasma | |
| CN215115454U (en) | Whole blood sample heparin binding protein separator | |
| EP2845001B1 (en) | Whole blood analytic device and method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |